GC Aesthetics reels in $20M Series D

Dublin
Courtesy of Donaldytong CC BY-SA 3.0

Irish breast implant maker GC Aesthetics completed a $20 million Series D round. The financing will help the company ramp up its commercial operations.

Existing investors Barry’s Tea Holdings, Montreux Equity Partners and Oyster Capital participated, according to a statement. GC Aesthetics previously raised $60 million in 2014, $40 million of which came from new investor Orbimed, with the remaining $20 million from investors including Montreux and Oyster Capital.

The company will use the funds to continue its expansion outside the U.S. These efforts include investing in innovation, improving customer service and launching its leading Impleo product globally, according to the statement.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

GC Aesthetics markets breast implants in more than 75 countries and has about 400 employees. It manufactures more than 325,000 implants each year and last year expanded its customer base by more than 60%, the company said in the statement.

It is the parent company of U.K.-based Nagor and France-based Eurosilicone, both makers of breast implants. It also makes Silgel, which can reduce the appearance of postsurgery scars.

- here's the statement

Related Articles:
Sientra resumes U.S. sales of breast implants after Brazil manufacturing fallout
Sientra slides amid implant manufacturing fallout in Brazil
Upstart Establishment gets $20M+ to bring safer breast implants with nanotech, RFID tracking to U.S.
PIP breast implant scandal a boon to U.K. company

Read more on

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.